Vaxcyte, Inc. Vaxcyte, Inc.

Vaxcyte, Inc.

PCVX

Kedudukan dalam Saham #2070
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Harga Saham
$64.29
Modal Pasaran
$9.86B
Perubahan (1 hari)
1.05%
Perubahan (1 tahun)
51.66%
Negara
US
Perdagangan Vaxcyte, Inc. (PCVX)

Kategori

Healthcare
Sejarah pecahan saham untuk Vaxcyte, Inc. (PCVX)
Saham Vaxcyte, Inc. (simbol: PCVX) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 19, 2026.
Satu saham PCVX yang dibeli sebelum Oct 19, 2026 kini bersamaan dengan 0 saham PCVX.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
Tidak cukup data untuk tarikh yang disediakan.
Pecahan saham untuk syarikat pesaing atau serupa
Syarikat Bilangan pecahan saham Gandaan Kumulatif Negara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL